MIRO2 (Mitochondrial Rho GTPase 2), also known as RHOT2, is a mitochondrial outer membrane GTPase encoded by the RHOT2 gene on chromosome 16p13.3. Together with its paralog MIRO1 (RHOT1), MIRO2 is a central component of the mitochondrial transport machinery that regulates the movement, positioning, and dynamics of mitochondria within neurons[1]. MIRO2 functions as a calcium-sensitive adaptor linking mitochondria to motor protein complexes (kinesin and dynein) through the adaptor proteins Milton/TRAK1/TRAK2, enabling bidirectional transport along microtubule tracks[2]. In neurons, where mitochondria must travel enormous distances from the soma to distal synapses and axon terminals, MIRO-dependent transport is essential for maintaining local ATP production, calcium buffering, and synaptic function. Dysregulation of MIRO2-mediated mitochondrial transport and quality control is implicated in Parkinson's disease, Alzheimer's disease, and Huntington's disease[3][4].
| Attribute | Value |
|---|---|
| Protein Name | Mitochondrial Rho GTPase 2 |
| Gene Symbol | RHOT2 |
| Aliases | MIRO2, ARHI2, C16orf52 |
| UniProt ID | Q8IXI2 |
| Protein Length | 618 amino acids |
| Molecular Weight | ~68 kDa |
| Chromosomal Location | 16p13.3 |
| Subcellular Localization | Mitochondrial outer membrane |
MIRO2 has a unique domain architecture among Rho-family GTPases, consisting of five domains arranged from N- to C-terminus[1:1][2:1]:
The tandem EF-hand domains are the critical calcium-sensing elements. At resting cytosolic Ca²⁺ (~100 nM), MIRO2 maintains its interaction with the TRAK/Milton-motor complex, enabling mitochondrial transport. When local Ca²⁺ rises (>1 μM), Ca²⁺ binding to the EF-hands triggers a conformational change that disrupts the MIRO2-TRAK-kinesin complex, arresting mitochondrial movement[2:2][5]. This calcium-dependent arrest mechanism positions mitochondria at sites of high energy demand and calcium buffering need, such as active synapses.
MIRO2 is essential for long-range mitochondrial transport in neurons. It anchors the TRAK1/TRAK2 adaptor proteins to the mitochondrial surface, which in turn recruit kinesin-1 (KIF5) for anterograde transport toward axon terminals and cytoplasmic dynein for retrograde transport toward the soma[1:2][2:3]. The choice of transport direction is regulated by:
At active synapses, glutamate receptor activation and voltage-gated calcium channel opening produce local Ca²⁺ transients. MIRO2's EF-hands sense these transients and arrest mitochondrial transport, accumulating mitochondria at sites where ATP production and Ca²⁺ buffering are most needed[5:1]. This "activity-dependent mitochondrial docking" is critical for sustained synaptic transmission.
MIRO2 intersects with the PINK1/Parkin mitophagy pathway. When mitochondria become depolarized, PINK1 accumulates on their outer membrane and recruits Parkin, an E3 ubiquitin ligase. Parkin ubiquitinates MIRO2, targeting it for proteasomal degradation. MIRO2 degradation disconnects damaged mitochondria from the transport machinery, quarantining them for autophagic clearance[3:1][6]. This PINK1-Parkin-MIRO2 axis ensures that dysfunctional mitochondria are not transported to distant neuronal compartments.
MIRO2 influences mitochondrial fission and fusion balance through interactions with MFN1/MFN2 (mitofusins) and DRP1. MIRO2 stabilizes mitofusin complexes at mitochondrial contact sites, promoting fusion. Loss of MIRO2 shifts the balance toward excessive fission, generating fragmented mitochondria[1:3].
MIRO2 is directly linked to Parkinson's disease through the PINK1/Parkin pathway:
In Alzheimer's disease, mitochondrial transport defects are an early pathological feature:
Mutant huntingtin disrupts MIRO-dependent mitochondrial transport in striatal neurons, contributing to the selective vulnerability of medium spiny neurons in Huntington's disease. Huntingtin normally facilitates MIRO-TRAK interactions; polyglutamine expansion impairs this scaffolding function[4:3].
| Strategy | Mechanism | Status |
|---|---|---|
| MIRO2 reducers | Small molecules promoting MIRO2 degradation to enhance mitophagy | Discovery (compound screening) |
| MIRO2 EF-hand modulators | Tuning calcium sensitivity of mitochondrial arrest | Conceptual |
| Parkin activation | Enhance Parkin-mediated MIRO2 ubiquitination on damaged mitochondria | Preclinical |
| TRAK1/2 modulation | Alter adaptor recruitment to shift transport dynamics | Early research |
Aspenstrom P. A Cdc42 target protein with homology to the non-kinase domain of FER has a potential role in regulating the actin cytoskeleton. Current Biology. 2000. ↩︎ ↩︎ ↩︎ ↩︎
Schwarz TL. Mitochondrial trafficking in neurons. Cold Spring Harbor Perspectives in Biology. 2013. ↩︎ ↩︎ ↩︎ ↩︎
Wang X, Winter D, Bhatt DK, et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell. 2011. ↩︎ ↩︎ ↩︎
Panchal K, Bhatt DK. Miro, a Rho GTPase genetically interacts with Alzheimer's disease-associated genes. Frontiers in Aging Neuroscience. 2022. ↩︎ ↩︎ ↩︎ ↩︎
Saotome M, Safiulina D, Bhatt DK, et al. Bidirectional Ca2+-dependent control of mitochondrial dynamics by the Miro GTPase. Proceedings of the National Academy of Sciences. 2008. ↩︎ ↩︎
Birsa N, Norkett R, Wauer T, et al. Lysine 27 ubiquitination of the mitochondrial transport protein Miro is dependent on serine 65 of the Parkin ubiquitin ligase. Journal of Biological Chemistry. 2014. ↩︎ ↩︎ ↩︎
Hsieh CH, Shaltouki A, Goldman AE, et al. Functional impairment in Miro degradation and mitophagy is a shared feature in familial and sporadic Parkinson's disease. Cell Stem Cell. 2016. ↩︎